Hexarelin vs Ghrelin: How Their Receptor Pharmacology Compares

Introduction

Hexarelin and ghrelin are often mentioned in the same breath because both act on the growth hormone secretagogue receptor, GHS-R1a. Yet one is a 28-residue hormone carrying a fatty-acid tag, and the other is a six-residue synthetic peptide with no such tag. Both are discussed here strictly as research materials: for research use only, not for human or animal consumption. Research-grade material is also not equivalent to any FDA-approved product.

Why compare them? Papers on these two ligands are easy to misread. A result seen with one gets assumed for the other, and receptor claims often run ahead of the evidence. Here we walk through the ligands, the receptor, the second target hexarelin appears to have, and the points where the literature is still unsettled.

Ghrelin as the endogenous ligand

Short answer: ghrelin is the body's own GHS-R1a ligand, and a lipid modification is what lets it work.

A 28-residue peptide with a lipid tag

Ghrelin is a 28-amino-acid peptide. Its third residue, a serine, carries an eight-carbon octanoyl group. The enzyme that attaches it is ghrelin O-acyltransferase (GOAT, also called MBOAT4). According to a 2021 review in Open Biology, ghrelin is the only human protein known to carry this modification and the only substrate of GOAT in the human proteome. For the chemistry in more detail, see our pieces on ghrelin octanoylation and the GOAT enzyme.

Why acylation decides receptor activation

The same review states plainly that "to bind and activate GHS-R1a, ghrelin must be acylated." The proposed binding site has a polar region that contacts ghrelin's N-terminal residues and a nonpolar surface that seats the octanoyl group. Without the lipid, the peptide doesn't activate the receptor, a point echoed in the 2026 Indian Journal of Pharmacology paper on hexarelin and retinal cells.

That lipid is also a weak point. Circulating esterases remove it in blood, with butyrylcholinesterase, alpha-2-macroglobulin, APT1 and Notum named as candidates. The unacylated form, des-acyl ghrelin, was once treated as inert. Researchers have since reported effects on insulin release, cell survival and adipogenesis, but its mechanism of action, in the review's words, "remains undefined."

Hexarelin as a synthetic hexapeptide

Short answer: hexarelin reaches the same receptor with a much smaller peptide and no lipid tag.

Six residues instead of twenty-eight

Hexarelin is a synthetic hexapeptide. Papers describe it as binding GHS-R1a with high affinity, which is why it is used as a reference secretagogue in receptor studies. It needs no GOAT-dependent modification, so acylation never enters the picture. For a comparison against a smaller secretagogue, see Ipamorelin vs Hexarelin.

Stability and potency descriptions

A 2021 study in Pharmaceuticals describes hexarelin as "chemically more stable and functionally more potent when compared with ghrelin." The 2026 retinal paper adds that hexarelin has a longer half-life than ghrelin in pharmacokinetic studies.

Two cautions apply. First, the half-life comparison is indirect: it draws on separate rat studies run under different conditions, not a head-to-head experiment. Second, none of the sources reviewed here report a binding constant (Ki or IC50) for hexarelin at GHS-R1a, so this article does not quote one. "More potent" is a descriptive phrase from reviews, not a number we can hand you.

GHS-R1a, a receptor that signals on its own

Short answer: the receptor is active even with no ligand present, which changes how any ligand should be read.

High constitutive activity

GHS-R1a is a class A G-protein-coupled receptor found mainly in the hypothalamus and pituitary. A 2013 review in Frontiers in Neuroscience defines constitutive activity as "the ability to propagate the intracellular signal in the absence of agonist" and reports that GHS-R1a signals at about 50% of its maximal capacity with no ghrelin at all. That baseline drives phospholipase C and inositol phosphate signaling, protein kinase C and CRE-dependent signaling, plus a constitutive, beta-arrestin-independent internalization of the receptor.

Structurally, aromatic residues on the inner face of transmembrane helices VI and VII, including Trp276, help hold the receptor in an active state, and flexibility in the second extracellular loop contributes to basal signaling. A naturally occurring Ala204Glu change in that loop abolishes constitutive activity and has been associated with familial short stature.

What that means for comparing ligands

The receptor already hums along at roughly half capacity. So an agonist such as ghrelin or hexarelin adds to a baseline; it doesn't switch the receptor on from zero. An inverse agonist does the opposite: a substance P analog carrying D-Arg1, D-Phe5, D-Trp7,9 and Leu11 substitutions undoes the constitutive signal and traps the receptor at the cell surface. Ghrelin binds the middle of the pocket, while that analog occupies an extended pocket spanning seven transmembrane domains. How agonist signaling fades with time is covered in GHS-R1a desensitization.

One receptor or two: CD36 and unresolved mechanism

Short answer: hexarelin has a second known target, and some of its effects may not involve GHS-R1a at all.

CD36 as a second hexarelin target

The Pharmaceuticals study notes that hexarelin "binds not only to the GHS-R1a but also the CD36 receptor." CD36 is a different kind of protein altogether, not a GPCR in the ghrelin family. The retinal paper likewise calls CD36 another hexarelin receptor and mentions anticonvulsant-type findings in animal models linked to it. Ghrelin is not described in these sources as acting on CD36, so target breadth is a real pharmacological difference between the two ligands.

When GHS-R1a does not explain the result

Several cell and tissue studies complicate the picture:

• In mouse Neuro-2A cells, 1 µM hexarelin alone did not change viability, but alongside 100 µM hydrogen peroxide it attenuated the damage and shifted MAPK and PI3K/Akt signaling. The authors say it is unclear whether GHS-R1a mediated this, and no receptor-blocking experiments were done.
• In hippocampal progenitor cells, the anti-apoptotic effect did not appear to depend on GHSR1a, and ghrelin was ineffective in the same setting.
• In the retinal study, a GHSR1a antagonist did not block hexarelin's effect, so the author states the receptor mechanism is unresolved.

All of these are in vitro or animal findings in single model systems, and they should be read that way. The honest summary is that GHS-R1a clearly accounts for hexarelin's growth hormone secretagogue pharmacology, while its other cellular effects may involve CD36, other receptors or both.

Endogenous brakes: LEAP2 and receptor partners

Short answer: ghrelin signaling has built-in off switches that synthetic ligands may or may not share.

Ghrelin does not act on an unregulated receptor. A 2020 review in Trends in Endocrinology & Metabolism covers LEAP2, a liver-derived peptide that fully inhibits ghrelin activation of GHS-R1a (IC50 about 6 nM) and blocks major ghrelin effects in vivo. The same review describes GHS-R1a's ability to form dimers with other GPCRs and to be tuned by interacting proteins, widening the signaling picture well beyond a simple lock-and-key model.

The sources reviewed here do not compare how LEAP2 behaves against hexarelin versus ghrelin, so that remains an open question rather than a claim we can make.

Side-by-side summary

The main contrasts, in brief. Ghrelin is a 28-residue endogenous peptide that must be octanoylated on Ser-3 by GOAT to engage GHS-R1a, and it is deacylated by blood esterases. Hexarelin is a six-residue synthetic peptide that binds GHS-R1a with high affinity without any lipid modification, and is described as more chemically stable. Ghrelin is described as acting through GHS-R1a, whereas hexarelin also binds CD36 and shows effects in some systems that do not track GHS-R1a. Ghrelin signaling is checked by LEAP2 and by the receptor's own constitutive behavior; the equivalent data for hexarelin are not in the sources reviewed.

Conclusion

Same receptor, different chemistry, different target list. Ghrelin depends on a lipid tag, an enzyme and a regulated hormonal context. Hexarelin is a compact synthetic peptide that reaches GHS-R1a without the tag and also engages CD36. When you read a paper that attributes a cellular effect to one of them, check whether receptor involvement was actually tested, whether the model was in vitro or in an animal, and whether a comparison to the other ligand was direct or inferred. The articles linked above are a good next step.

Frequently Asked Questions

Do hexarelin and ghrelin bind the same receptor?

Both bind GHS-R1a, a class A GPCR found mainly in the hypothalamus and pituitary. Hexarelin also binds CD36, which ghrelin is not described as targeting in the sources reviewed.

Why does ghrelin need an octanoyl group?

The octanoyl group on Ser-3, added by the enzyme GOAT, is required for ghrelin to bind and activate GHS-R1a. Unacylated ghrelin does not activate the receptor.

Is hexarelin more stable than ghrelin?

Reviews describe hexarelin as chemically more stable, and one author cites a longer half-life from separate animal studies. That is an indirect comparison, not a head-to-head measurement.

Does hexarelin always work through GHS-R1a?

Not necessarily. In some cells lacking GHSR1a, and in one retinal study where a GHSR1a antagonist did not block the effect, the mechanism remains unresolved.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.